Literature DB >> 32016080

The importance of antiandrogen in prostate cancer treatment.

Camille Lanz1, Mostefa Bennamoun2, Petr Macek1, Xavier Cathelineau1, Rafael Sanchez-Salas1.   

Abstract

Entities:  

Year:  2019        PMID: 32016080      PMCID: PMC6976485          DOI: 10.21037/atm.2019.09.53

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  25 in total

1.  Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Authors:  Silke Gillessen; Gerhardt Attard; Tomasz M Beer; Himisha Beltran; Alberto Bossi; Rob Bristow; Brett Carver; Daniel Castellano; Byung Ha Chung; Noel Clarke; Gedske Daugaard; Ian D Davis; Johann de Bono; Rodolfo Borges Dos Reis; Charles G Drake; Ros Eeles; Eleni Efstathiou; Christopher P Evans; Stefano Fanti; Felix Feng; Karim Fizazi; Mark Frydenberg; Martin Gleave; Susan Halabi; Axel Heidenreich; Celestia S Higano; Nicolas James; Philip Kantoff; Pirkko-Liisa Kellokumpu-Lehtinen; Raja B Khauli; Gero Kramer; Chris Logothetis; Fernando Maluf; Alicia K Morgans; Michael J Morris; Nicolas Mottet; Vedang Murthy; William Oh; Piet Ost; Anwar R Padhani; Chris Parker; Colin C Pritchard; Mack Roach; Mark A Rubin; Charles Ryan; Fred Saad; Oliver Sartor; Howard Scher; Avishay Sella; Neal Shore; Matthew Smith; Howard Soule; Cora N Sternberg; Hiroyoshi Suzuki; Christopher Sweeney; Matthew R Sydes; Ian Tannock; Bertrand Tombal; Riccardo Valdagni; Thomas Wiegel; Aurelius Omlin
Journal:  Eur Urol       Date:  2017-06-24       Impact factor: 20.096

2.  Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

Authors:  Ian D Davis; Andrew J Martin; Martin R Stockler; Stephen Begbie; Kim N Chi; Simon Chowdhury; Xanthi Coskinas; Mark Frydenberg; Wendy E Hague; Lisa G Horvath; Anthony M Joshua; Nicola J Lawrence; Gavin Marx; John McCaffrey; Ray McDermott; Margaret McJannett; Scott A North; Francis Parnis; Wendy Parulekar; David W Pook; M Neil Reaume; Shahneen K Sandhu; Alvin Tan; T Hsiang Tan; Alastair Thomson; Emily Tu; Francisco Vera-Badillo; Scott G Williams; Sonia Yip; Alison Y Zhang; Robert R Zielinski; Christopher J Sweeney
Journal:  N Engl J Med       Date:  2019-06-02       Impact factor: 91.245

3.  Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

Authors:  Kim N Chi; Neeraj Agarwal; Anders Bjartell; Byung Ha Chung; Andrea J Pereira de Santana Gomes; Robert Given; Álvaro Juárez Soto; Axel S Merseburger; Mustafa Özgüroğlu; Hirotsugu Uemura; Dingwei Ye; Kris Deprince; Vahid Naini; Jinhui Li; Shinta Cheng; Margaret K Yu; Ke Zhang; Julie S Larsen; Sharon McCarthy; Simon Chowdhury
Journal:  N Engl J Med       Date:  2019-05-31       Impact factor: 91.245

Review 4.  Complete androgen blockade for the treatment of prostate cancer.

Authors:  F Labrie; A Dupont; A Belanger
Journal:  Important Adv Oncol       Date:  1985

5.  Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

Authors:  Dana E Rathkopf; Michael J Morris; Josef J Fox; Daniel C Danila; Susan F Slovin; Jeffrey H Hager; Peter J Rix; Edna Chow Maneval; Isan Chen; Mithat Gönen; Martin Fleisher; Steven M Larson; Charles L Sawyers; Howard I Scher
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

6.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

Authors:  E D Crawford; M A Eisenberger; D G McLeod; J T Spaulding; R Benson; F A Dorr; B A Blumenstein; M A Davis; P J Goodman
Journal:  N Engl J Med       Date:  1989-08-17       Impact factor: 91.245

7.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

Authors:  Christopher J Sweeney; Yu-Hui Chen; Michael Carducci; Glenn Liu; David F Jarrard; Mario Eisenberger; Yu-Ning Wong; Noah Hahn; Manish Kohli; Matthew M Cooney; Robert Dreicer; Nicholas J Vogelzang; Joel Picus; Daniel Shevrin; Maha Hussain; Jorge A Garcia; Robert S DiPaola
Journal:  N Engl J Med       Date:  2015-08-05       Impact factor: 91.245

9.  Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.

Authors:  David F Penson; Andrew J Armstrong; Raoul Concepcion; Neeraj Agarwal; Carl Olsson; Lawrence Karsh; Curtis Dunshee; Fong Wang; Kenneth Wu; Andrew Krivoshik; De Phung; Celestia S Higano
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

10.  Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.

Authors:  R A Janknegt; C C Abbou; R Bartoletti; L Bernstein-Hahn; B Bracken; J M Brisset; F C Da Silva; G Chisholm; E D Crawford; F M Debruyne
Journal:  J Urol       Date:  1993-01       Impact factor: 7.450

View more
  1 in total

Review 1.  TLX, an Orphan Nuclear Receptor With Emerging Roles in Physiology and Disease.

Authors:  Adam T Nelson; Yu Wang; Erik R Nelson
Journal:  Endocrinology       Date:  2021-11-01       Impact factor: 5.051

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.